Q4'23 results due 30 January. 5.4% organic sales growth and margin uplift in Q4e. Adj EBITDA revised down 0.6%-4.9% mainly due to FX. BUY.

15 Jan 2024
Earnings recovery continues

Sign up to access
Get access to our full offering from over 100 providers
Get access to our full offering from over 100 providers
Earnings recovery continues
- Published:
15 Jan 2024 -
Author:
ABGSC Healthcare Research | Sten Gustafsson -
Pages:
16 -
Q4'23 results due 30 January. 5.4% organic sales growth and margin uplift in Q4e. Adj EBITDA revised down 0.6%-4.9% mainly due to FX. BUY.